Thursday, October 15, 2026

Luna Innovations Incorporated And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Luna Innovations Incorporated  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - Omega Healthcare Investors (OHI), Luna Innovations Incorporated (LUNA), Gerdau S.A. (GGB) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Omega Healthcare Investors (OHI)

130% sales growth and 5.63% return on equity

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities.

Omega Healthcare Investors's sales growth this year is expected to be 22.8% and 2.5% for next year.

Year-on-year quarterly revenue growth grew by 8.2%, now sitting on 913.12M for the twelve trailing months.

Volume

Today's last reported volume for Omega Healthcare Investors is 1756050 which is 9.66% below its average volume of 1943890.

Omega Healthcare Investors's sales growth for the next quarter is 130%. The company's growth estimates for the present quarter and the next is a negative 4.7% and 202.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.63%.

Volatility

Omega Healthcare Investors's last day, last week, and last month's current volatility was 0.85%, 0.69%, and 1.11%, respectively.

Omega Healthcare Investors's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.75% (day), 1.70% (last week), and 2.26% (last month), respectively.

Omega Healthcare Investors's Stock Yearly Top and Bottom Value

Omega Healthcare Investors's stock is valued at $37.19 at 05:22 EST, below its 52-week high of $39.31 and way above its 52-week low of $28.08.

Omega Healthcare Investors's Moving Average

Omega Healthcare Investors's worth is above its 50-day moving average of $36.85 and above its 200-day moving average of $36.96.

2. Luna Innovations Incorporated (LUNA)

54.7% sales growth and 5.67% return on equity

Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide.

Luna Innovations Incorporated's sales growth this year is expected to be 49.6% and 13.3% for next year.

Year-on-year quarterly revenue growth grew by 53.4%, now sitting on 91.84M for the twelve trailing months.

Volume

Today's last reported volume for Luna Innovations Incorporated is 54380 which is 63.61% below its average volume of 149452.

Luna Innovations Incorporated's sales growth for the next quarter is 54.7%. The company's growth estimates for the current quarter and the next is a negative 0% and negative -30.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.67%.

Volatility

Luna Innovations Incorporated's last day, last week, and last month's current volatility was 1.08%, 1.35%, and 2.56%, respectively.

Luna Innovations Incorporated's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.08% (day), 2.45% (last week), and 3.97% (last month), respectively.

Luna Innovations Incorporated's Stock Yearly Top and Bottom Value

Luna Innovations Incorporated's stock is valued at $10.35 at 05:22 EST, way under its 52-week high of $13.05 and way above its 52-week low of $4.93.

Luna Innovations Incorporated's Moving Average

Luna Innovations Incorporated's worth is under its 50-day moving average of $10.59 and under its 200-day moving average of $10.96.

3. Gerdau S.A. (GGB)

54% sales growth and 14.49% return on equity

Gerdau S.A. provides steel products and services in the United States and Canada.

Gerdau S.A.'s sales growth this year is expected to be 55.7% and a negative 7.6% for next year.

Year-on-year quarterly revenue growth grew by 77.1%, now sitting on 50.93B for the twelve trailing months.

Volume

Today's last reported volume for Gerdau S.A. is 365411 which is 98.07% below its average volume of 18914900.

Gerdau S.A.'s sales growth for the next quarter is 54%. The company's growth estimates for the present quarter and the next is 1650% and 244.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.49%.

Volatility

Gerdau S.A.'s last day, last week, and last month's current volatility was 0.99%, 2.27%, and 2.65%, respectively.

Gerdau S.A.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.53% (day), 3.59% (last week), and 3.84% (last month), respectively.

Gerdau S.A.'s Stock Yearly Top and Bottom Value

Gerdau S.A.'s stock is valued at $5.62 at 05:22 EST, way under its 52-week high of $7.27 and way above its 52-week low of $2.96.

Gerdau S.A.'s Moving Average

Gerdau S.A.'s value is below its 50-day moving average of $6.15 and higher than its 200-day moving average of $5.44.

4. MUELLER WATER PRODUCTS (MWA)

6% sales growth and 11.83% return on equity

Mueller Water Products, Inc. manufactures and markets products and services for use in the transmission, distribution, and measurement of water in the United States, Canada, and internationally.

MUELLER WATER PRODUCTS's sales growth this year is expected to be 9.4% and 4.1% for next year.

Year-on-year quarterly revenue growth grew by 3.8%, now sitting on 998.7M for the twelve trailing months.

Volume

Today's last reported volume for MUELLER WATER PRODUCTS is 823462 which is 7.76% above its average volume of 764131.

MUELLER WATER PRODUCTS's sales growth is a negative 0% for the present quarter and 6% for the next. The company's growth estimates for the current quarter and the next is 45.5% and 11.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.83%.

Volatility

MUELLER WATER PRODUCTS's last day, last week, and last month's current volatility was 0.91%, 0.83%, and 1.16%, respectively.

MUELLER WATER PRODUCTS's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.76% (day), 1.30% (last week), and 1.74% (last month), respectively.

MUELLER WATER PRODUCTS's Stock Yearly Top and Bottom Value

MUELLER WATER PRODUCTS's stock is valued at $14.91 at 05:22 EST, below its 52-week high of $15.05 and way above its 52-week low of $8.92.

MUELLER WATER PRODUCTS's Moving Average

MUELLER WATER PRODUCTS's value is higher than its 50-day moving average of $14.33 and higher than its 200-day moving average of $13.62.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com